LNDG: Mirabegron for overactive bladder

· London New Drugs Group

This review evaluates the evidence supporting the use of mirabegron, the first beta-3-adrenoceptor agonist, for the treatment of overactive bladder

NOTE: The content of this resource has not been updated since the publication date. Some information may be out of date and links to other documents or website may not work.


MirabegronNew MedicinesRenal and urologic disorders